• 1
    Schott HC, Pituitary pars intermedia dysfunction: Equine Cushing's disease. Vet Clin North Am Equine Pract 2002; 18: 237270.
  • 2
    Couetil L., Paradis MR, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996;10:16.
  • 3
    Donaldson MT, LaMonte BH, Morresey P., et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). J Vet Intern Med 2002;16:742746.
  • 4
    Dybdal NO, Hargreaves KM, Madigan JE, et al. Diagnostic testing for pituitary pars intermedia dysfunction in horses. J Am Vet Med Assoc 1994;204:627632.
  • 5
    Eiler H., Oliver JW, Andrews FM, et al. Results of a combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test in healthy horses and horses suspected to have a pars intermedia pituitary adenoma. J Am Vet Med Assoc 1997;211:7981.
  • 6
    Loong TW. Understanding sensitivity and specificity with the right side of the brain. Br Med J 2003;327:716719.
  • 7
    Donaldson MT, Jorgensen AJ, Beech J. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis. J Am Vet Med Assoc 2004;224:11231127.
  • 8
    Perkins GA, Lamb S., Erb HN, et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide. Equine Vet J 2002;34:679685.
  • 9
    Freestone JF, Wolfsheimer KJ, Kamerling SG, et al. Exercise induced hormonal and metabolic changes in Thoroughbred horses: Effects of conditioning and acepromazine. Equine Vet J 1991;23:219223.
  • 10
    Van der Kolk JH, Heinrichs M., Van Amerongen JD, et al. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma. Am J Vet Res 2004;65:17011707.
  • 11
    Beech J., Garcia M. Hormonal response to thyrotropin-releasing hormone in healthy horses and in horses with pituitary adenoma. Am J Vet Res 1985;46:19411943.
  • 12
    McFarlane D., Beech J., Cribb A. Alpha-melanocyte stimulating hormone release in response to thyrotropin releasing hormone in healthy horses, horses with pituitary pars intermedia dysfunction and equine pars intermedia explants. Domest Anim Endocrinol 2006;30:276288.
  • 13
    McFarlane D., Miller LM, Craig LE, et al. Agreement in histologic assessments of the pituitary pars intermedia in aged horses. Am J Vet Res 2005;66:20552059.
  • 14
    McFarlane D., Donaldson MT, McDonnell SM, et al. Effects of season and sample handling on measurement of plasma alpha-melanocyte-stimulating hormone concentrations in horses and ponies. Am J Vet Res 2004;65:14631468.
  • 15
    Orth DN, Nicholson WE. Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease. Endocrinology 1982;111:559563.
  • 16
    Donaldson MT, McDonnell SM, Schanbacher BJ, et al. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. J Vet Intern Med 2005;19:217222.
  • 17
    Evans DR. The recognition and diagnosis of a pituitary tumor in the horse. American Association of Equine Practitioners 18th Annual Meeting 1972; pp 417419.